One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

Table 3 Logistic regression analysis of ≥ 50% reponse et M6

Variables	Coefficient (b)	SE	Wald χ2	p-value	Adj OR	[95% CI]
MHD	-0.06	0.03	4.0	0.036	0.93	[0.89; 0.99]
Age	-0.04	0.02	4.4	0.045	0.96	[0.93; 0.99]
Psychiatric comorbidities (No vs Yes)	0.96	0.40	5.6	0.017	2.61	[1.19; 5.87]

ISSN: 1129-2377